本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Evaxion Biotech A/S

3.08
-0.1400-4.35%
盤後3.340.2571+8.35%19:47 EDT
成交量:3.38萬
成交額:10.47萬
市值:2,557.23萬
市盈率:-3.08
高:3.28
開:3.12
低:3.02
收:3.22
52周最高:12.15
52周最低:1.20
股本:830.27萬
流通股本:553.19萬
量比:1.16
換手率:0.61%
股息:- -
股息率:- -
每股收益(TTM):-1.0000
每股收益(LYR):-1.0000
淨資產收益率:-100.18%
總資產收益率:-28.23%
市淨率:1.50
市盈率(LYR):-3.08

資料載入中...

2026/03/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/11/21

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/04/01

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/21

SEC問詢函

Form CORRESP - Correspondence
2025/01/29

SEC問詢函

Form CORRESP - Correspondence
2025/01/28

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/12/18

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/12/05

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/11/18

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/11/14

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/07

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/20

SEC問詢函

Form CORRESP - Correspondence
2024/08/20

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/07/22

SEC問詢函

Form CORRESP - Correspondence
2024/07/22

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/05/06

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/03/26

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/31

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/01/31

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/01/30

SEC問詢函

Form CORRESP - Correspondence